Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexaria Bioscience Corp LEXX

Alternate Symbol(s):  LEXXW

Biotechnology
Lexaria Bioscience Corp. is a Canada-based biotechnology company. The Company's patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery. DehydraTECH has also evidenced an ability to deliver some drugs effectively across the blood brain barrier. It is advancing several research and development (R&D) activities in both preclinical and clinical programs. Its primary research programs are the investigation of optimal formulations of DehydraTECH-enhanced glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) drugs as well as the investigation of cannabidiol (CBD) for the reduction of hypertension leading to a cleared IND application by the United States Food and Drug Administration. It operates a licensed in-house research laboratory and holds an intellectual property portfolio with around 46 patents granted and many patents pending worldwide.


NDAQ:LEXX - Post by User

Lexaria Bioscience Corp
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(731)
•••
Post by yowkonasaearthon Mar 09, 2021 10:47am
154 Views
Post# 32752093

Nickel's Updated Today!

Nickel's Updated Today!

Sponsored Post Why do you think there could be a potential demand for Nickel and Lithium in the First Place? Lets take a look in this updated information here. Try to click this one!

It is said that, these metals are not getting enough recognition as they should. There expanding potential demand for electric vehicles (EVs) in an inflation climate-conscious worldwide society. According to the news, total EV demand could potentially move from about approx. 2.5 million in 2020 to approximately 11.2 million in 2025, then reach around approx. 31.1 million by 2030. It is no wonder that these other companies are now the most valuable automaker in the world in terms of market cap.

But what do you think is powering these cars? Do you have any idea? Check disclaimer on profile and landing page.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities